We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Biosearch Technologies Takes License to CDC H1N1 Signatures and Influenza a Sub-Typing Patent
News

Biosearch Technologies Takes License to CDC H1N1 Signatures and Influenza a Sub-Typing Patent

Biosearch Technologies Takes License to CDC H1N1 Signatures and Influenza a Sub-Typing Patent
News

Biosearch Technologies Takes License to CDC H1N1 Signatures and Influenza a Sub-Typing Patent

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Biosearch Technologies Takes License to CDC H1N1 Signatures and Influenza a Sub-Typing Patent"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Biosearch becomes the first to license these CDC Influenza signatures. The license confers to Biosearch rights under the CDC patents to manufacture and sell oligonucleotides bearing the H1N1 and Influenza A sub-typing signatures. 

Marc Beal, Director of Corporate Development at Biosearch Technologies, comments, “By licensing these CDC Influenza patents, Biosearch becomes the first authorized licensed supplier of CDC H1N1 and Influenza Sub-typing Panel sequences.  Combined with the Roche 5’ Nuclease probe patent license, Biosearch intends to provide dual labeled 5’ nuclease probes to the growing number of Roche licensed CLIA labs providing molecular diagnostic services.  The CDC H1N1 and Influenza Sub-typing panel signatures will be provided as custom ASRs, IVD and research quality oligo components.”

As the inventors of BHQ® (Black Hole Quencher®) technology which is fundamental to the performance of the CDC probes, Biosearch will provide access to gold standard 5’-Nuclease BHQ probes for H1N1 testing labs around the world.

Advertisement